Universität zu Köln

Martel, Samuel, Maurer, Christian, Lambertini, Matteo ORCID: 0000-0003-1797-5296, Ponde, Noam and De Azambuja, Evandro (2017). Breast cancer treatment-induced cardiotoxicity. Expert Opin. Drug Saf., 16 (9). S. 1021 - 1039. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-764X

Full text not available from this repository.

Abstract

Introduction: Breast cancer is the most frequent cancer affecting women worldwide. In every setting, the majority of women are treated with an evergrowing arsenal of therapeutic agents that have greatly improved their outcomes. However, these therapies can also be associated with significant adverse events. Areas covered: This review aims to thoroughly describe the current state of the evidence regarding the potential cardiotoxicity of agents commonly used in the treatment of breast cancer. These include chemotherapeutic agents, anti-HER2 therapies and CDK4/6 and mTOR inhibitors. Furthermore, issues related to the risk stratification and monitoring tools are explored. Expert opinion: Anthracycline-and trastuzumab-related cardiac toxicities have been extensively studied. Substantial evidence is now available concerning additional anti-HER2 agents such as pertuzumab, T-DM1 and tyrosine kinase inhibitors; overall, the cardiotoxicity profile is reassuring. Cardiac events due to endocrine therapy are mostly ischemic and, in the context of prolonged therapy, need specific attention. Novel agents implicated in the treatment of hormone receptor-positive disease are potentially arrhythmogenic and the exact risk will need to be further refined. As for today, assessment of baseline risk factors prior to treatment initiation and cardiac imaging before and during treatment remains the optimal way to prevent cardiac dysfunction. Cardioprotective therapy in primary prevention is still a matter of debate.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Martel, Samuel UNSPECIFIED UNSPECIFIED UNSPECIFIED Maurer, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Lambertini, Matteo UNSPECIFIED orcid.org/0000-0003-1797-5296 UNSPECIFIED Ponde, Noam UNSPECIFIED UNSPECIFIED UNSPECIFIED De Azambuja, Evandro UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-245634
DOI:	10.1080/14740338.2017.1351541
Journal or Publication Title:	Expert Opin. Drug Saf.
Volume:	16
Number:	9
Page Range:	S. 1021 - 1039
Date:	2017
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1744-764X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GROWTH-FACTOR RECEPTOR; LAPATINIB PLUS CAPECITABINE; PHASE-II TRIAL; TRASTUZUMAB EMTANSINE T-DM1; TYROSINE KINASE INHIBITOR; ERBB FAMILY BLOCKER; 7-YEAR FOLLOW-UP; OPEN-LABEL; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN Multiple languages Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24563